In Vitro Activities of Ceftazidime-Avibactam and Aztreonam-Avibactam at Different Inoculum Sizes of Extended-Spectrum beta-Lactam-Resistant Enterobacterales Blood Isolates

beta-lactam-avibactam combinations have been proposed as carbapenem-sparing therapies, but little data exist on their in vitro activities in infections with high bacterial inocula. We investigated the in vitro efficacies and the inoculum effects of ceftazidime-avibactam and aztreonam-avibactam against extended-spectrum beta-lactam-resistant Enterobacterales blood isolates. A total of 228 non-repetitive extended-spectrum beta-lactam-resistant Escherichia coli and Klebsiella pneumoniae blood isolates were prospectively collected in a tertiary center. In vitro susceptibilities to ceftazidime, aztreonam, meropenem, ceftazidime-avibactam, and aztreonam-avibactam were evaluated by broth microdilution method using standard and high inocula. An inoculum effect was defined as an eightfold or greater increase in MIC when tested with the high inoculum. Of the 228 isolates, 99% were susceptible to ceftazidime-avibactam and 99% had low aztreonam-avibactam MICs (<= 8 mg/L). Ceftazidime-avibactam and aztreonam-avibactam exhibited good in vitro activities; MIC50/MIC90 values were 0.5/2 mg/L, 0.125/0.5 mg/L, and <= 0.03/0.25 mg/L, respectively, and aztreonam-avibactam was more active than ceftazidime-avibactam. The frequencies of the inoculum effect with ceftazidime-avibactam and aztreonam-avibactam were lower than with meropenem (14% vs. 38%, p < 0.001 and 30% vs. 38%, p = 0.03, respectively). The beta-lactam-avibactam combinations could be useful as carbapenem-sparing strategies, and aztreonam-avibactam has the better in vitro activity but is more subject to the inoculum effect than ceftazidime-avibactam.